Kit for double stranded RNA removal in beta testing with applications in vaccine manufacturing

Double stranded RNA (dsRNA) is a difficult to remove contaminant which is commonly present when manufacturing mRNA drugs, a recent publication in the journal of molecular therapeutics – nucleic acids, reveals some of the challenges. In consultation with multiple companies involved with COVID-19 vaccine manufacturing, Life Magnetics, Inc. has developed and is now beta-testing a kit for removing dsRNA from samples. The carbon technology works by binding to sp2 hybridized carbon which is only available in single stranded nucleic acids. The existing silica technologies separate molecules based on polarity. While both double and single stranded RNA have similar polarity, there is a significant difference in the available aromatic hydrocarbons. Leveraging this, we can easily purify mRNA for drug manufacturing including COVID-19 vaccine manufacturing.